A retrospective study of assessment of the risks for cardiovascular and renal events in patients who received agalsidase alfa for the treatment of Fabry's disease
Latest Information Update: 27 Nov 2020
At a glance
- Drugs Agalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- 27 Nov 2020 New trial record
- 17 Nov 2020 Results published in the Clinical Therapeutics